Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting

WALTHAM, Mass., April 11, 2016 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that entinostat will be the subject of seven investigator presentations, one oral and six posters, at the AACR Annual Meeting 2016 in New Orleans, Louisiana, highlighting entinostat’s potential use in combination approaches to treat various cancers. Details of the seven presentations are as follows:

1) Title: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)

Session Title: Early Clinical Trials of Agents Targeting DNA Repair of the Epigenome

Location: Room 291, Morial Convention Center

Date and Time: Sunday, April 17, 2106 4:15 PM-6:15 PM  

Abstract Number: CT015

2) Title: Overexpression of miRNAs 181a and 222 play a role in triple negative breast cancer, and are targeted by entinostat

Session Title: MicroRNAs as Biomarkers and Therapeutics

Location: Poster, Section 6

Date and Time: Monday, April 18, 2016, 8:00 AM-12:00 PM

Abstract Number: 1062

3) Title: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line

Session Title: Mechanisms and Applications of Immune-based Therapies

Location: Poster, Section 27

Date and Time: Tuesday, April 19, 2016, 1:00 PM-5:00 PM

Abstract Number: 4030

4) Title: The selective class 1 HDAC inhibitor entinostat enhances the antitumor effect of PD-1 inhibition in a syngeneic orthotopic murine model of renal cell carcinoma

Session Title: Immune Response Monitoring: Preclinical

Location: Poster, Section 23

Date and Time: Wednesday, April 20, 2016, 8:00 AM-12:00 PM

Abstract Number: 4906

5) Title: Epigenetic Treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: implications for response to immune checkpoint therapy

Session Title: Immune Responses Monitoring: Preclinical

Location: Poster, Section 23

Date and Time: Wednesday, April 20, 2016, 8:00 AM-12:00 PM

Abstract Number: 4907

6) Title: Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

Session Title: HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents

Location: Poster, Section 17

Date and Time: Wednesday, April 20, 2016, 8:00 AM-12:00 PM

Abstract Number: 4726

7) Title: Epigenetic vulnerabilities in ovarian cancer

Session Title: Epigenetic Biomarkers and Therapies

Location: Poster, Section 4

Date and Time: Wednesday, April 20, 2016, 8:00 AM-12:00 PM

Abstract Number: 4486

About Syndax Pharmaceuticals, Inc.

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer. Concurrently, Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for ovarian cancer. For more information on Syndax please visit www.syndax.com.

Investor and Media Contacts

Barbara Ryan
[email protected]
(646) 690-7639